Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06814522 · ClinicalTrials.gov registry record · Phase 1
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout
A Phase 1 study of Burnout and Burnout, Healthcare Workers, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06814522: Recruiting Phase 1 study of Burnout and Burnout, Healthcare Workers, sponsored by University of California, San Diego.
NCT06814522 is a Phase 1 study of Burnout and Burnout, Healthcare Workers that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 10 participants, below the 5,158-participant average among 18 other Burnout trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06814522, a Phase 1 study of Burnout and Burnout, Healthcare Workers, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms.
Primary Outcome
Assessment used to determine degree/severity of burnout.
Conditions Studied
Interventions
- DRUG Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate
Study Locations (1)
California
- UC San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT06814522 shows while recruiting
NCT06814522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 5,158-participant average among 18 other Burnout trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Burnout appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate is the first listed.
NCT06814522 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06814522 about?
NCT06814522 is a clinical study titled "Psilocybin-Assisted Therapy for Physician Well-Being and Burnout". Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms.
What is the current status of trial NCT06814522?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-01-13. Estimated completion is 2026-07.
What conditions does trial NCT06814522 study?
This clinical trial studies the following conditions: Burnout, Burnout, Healthcare Workers.
What interventions are being tested in trial NCT06814522?
The interventions under investigation include: Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (DRUG).
Who is sponsoring clinical trial NCT06814522?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06814522 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burnout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06814522's enrollment target sits among peer trials
10 19th of 18 the lowest of 18 other Burnout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burnout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Keck Medicine of University of Southern California Thrive Study
RECRUITING · NA
-
Vital Coach: A Study of Resiliency in Medical Students
RECRUITING · NA
-
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
RECRUITING · NA
-
The Work-life Check-ins: a Supervisor-driven Intervention to Reduce Burnout in Primary Care
RECRUITING · NA
-
Fostering Optimal Regulation of Emotion for Prevention of Secondary Trauma (FOREST)
RECRUITING · NA
-
Feasibility of Virtual Tai Chi Easy for Registered Nurses
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI